Navigation Links
FASTak™ Suture Anchor

ProductsFASTak™ Suture Anchor
Company Arthrex
Item FASTak™ Suture Anchor
Features 
  • Cortical bone soft tissue fixation
  • Bankart and SLAP repairs
  • Mini-open and arthroscopic insertion instrumentation
  • 2.4 mm diameter
    • Description The FASTak Suture Anchor is a fully threaded 2.4 mm diameter titanium suture anchor. It is inserted directly into bone without predrilling using either a powered handpiece or manually with the Tear Drop Handle and Keyless Chuck. This implant is ideal for Bankart and SLAP repairs as well as other small anchor indications with very high pull-out strengths. FASTak anchors are available with #2 FiberWire suture or Tevdek suture. Three styles of cannulated inserters are available to accurately position the anchor and to achieve an anatomic reconstruction. The FASTak Spear has a thin metal wall and is supplied with a trocar tipped obturator. The spear is ideal for percutaneous insertion during SLAP repairs and insertion through the subscapularis without using a cannula. The cannulated Clear Guide provides unsurpassed visualization of implants during insertion. The Cannulated FASTak Guide is an inserter that has a stiff metal wall and a large dovetail tip for accurate positioning on the glenoid rim. The stiff wall construction enables the surgeon to apply significant bending forces while leveraging soft tissue without damaging the instrument. It is recommended that a cannula be used with the cannulated Clear Guide and the metal cannulated guide.
    Info Arthrex
    Customer Service: (800) 933-7001
    Web site: http://www.arthrex.com

    Related medicine products :

    1. FASTak™ II Suture Anchor
    2. Serdarevic Suture Hook
    3. Castroviejo Suture Forceps
    4. OGawa Straight Suture-Fixation Forceps - 0.12 mm
    5. Colibri Suture Removal Forceps
    6. Paton Extra Delicate Suture Forceps
    7. Suture tying forceps
    8. Suture Removal Forceps #5a
    9. Micro Suture Forceps
    10. Suture Forceps
    11. Shutt® Suture Punch System
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    Medicine Products:
    (Date:9/5/2008)...an be controlled, but you need to know what trigge...5 (HealthDay News) -- If you are one of the 36 mil... there is nowhere in the United States that is fre... report shows. , Allergies don,t only happen in...ns as well. In the fall, the most challenging citi...
    (Date:9/5/2008)...ANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosurfa...eloper of less-invasive joint,resurfacing systems,...U.S.,FDA to begin its pivotal investigation for it... stated that "there are no outstanding safety,conc...tion., Arthrosurface has been evaluating the safe...
    (Date:9/5/2008)...e National Institute of Diabetes and Digestive and...titutes of Health (NIH), announces awards to eight...e studies of urologic chronic pelvic pain disorder...state. The total research investment for the five-...n. , "The launch of this novel research effort i...
    (Date:9/5/2008)...DLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Saturday...featured on the Oxygen Network show Today,s,Family... highlighted as a,leading medical device company t...h effective nebulizers and compressors that delive... vision is to improve the lives of those affected ...
    Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2
    ...’s Life of Life Healing Spa is increasingly gettin...ters of fat after the very first session. // Owner...ndergone the treatment with a good degree of succe...ire’ treatment when they opened in August. The fir...
    ...pecialists have expressed their disappointment ove...y have received transfusions of blood infected wit...t for this condition became available only in 1991...emophiliacs question the transfusion practice carr...
    ...d smoke has already been declared an air pollutant...onmental Protection Agency has also declared that ...esult of this, even though other groups like the C...n, the National Cancer Institute, and the American...
    ... William Honer and researchers have reported the r...cine in which they found in a trial conducted in 6...ntipsychotic drugs Clozapine and Risperdal for tre...s found that this combination drug did not work po...
    Other Medicine News:
    (Date:9/4/2008)...ort demonstrates potent antiviral activity and fav...e -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstC...X ), a biopharmaceutical company engaged,in the di... of human viral,and other infectious diseases, tod...ncept study evaluating IDX899, a non-nucleoside re...
    (Date:9/3/2008)... China, Sept. 3 /- Simcere,...facturer and supplier of,branded generic pharmaceu...r biotech product Endu (also known as Endostar) in...e IV clinical study., At the request of the SFDA,...rther validate the safety and therapeutic efficacy...
    (Date:9/3/2008)...BURG, Md., Sept. 3 /- Panacea Pharmac.... Patent Number 7,413,737 covering,antibodies agai...(HAAH), a,proprietary human cancer biomarker and t... in collaboration with the Massachusetts Institute...rldwide rights to this patent,for development of h...
    (Date:9/3/2008)...to be Evaluated in Repeat-Dosing Study in Subjects...FirstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq: ...2 clinical trial (SB-509-801) to evaluate its drug...enerative motor-neuron disease for which there,are...s drug, SB-509, is an injectable formulation of a ...
    Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5GNC Schedules Conference Call and Webcast to Report Third Quarter 2007 Financial Results 5274 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 2Report shows less than half of kids in California are being read to daily 5266 1Report shows less than half of kids in California are being read to daily 5266 2Report shows less than half of kids in California are being read to daily 5266 3Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 1Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 2Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 3
    ...ainst Cancer-Causing Virus,Types 16 & 18 That ...ion Levels, CHICAGO, June 05, 2007 /PRNewswire/ --...he first of a three-dose regimen, 100,percent of w...ine,(GSK) cervical cancer candidate vaccine had an...r-causing human papillomavirus,types, 16 and 18. T...
    ... these data reassuring", PHILADELPHIA, June 05, 20...today that findings from an interim analysis,of RE... and,Regulation of glycemia in Diabetes), a prospe...rmine cardiovascular outcomes in more,than 4,400 p...e to,the overall cardiovascular safety profile of ...
    Other Medicine Technology:Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5